A new therapy for liver cancer
Nicolas Melin is developing a new precision therapy for liver cancer in his Venture Fellowship project. In the video, he talks about the challenges involved in transferring research to industry.
Every year, around one million people worldwide are diagnosed with liver cell cancer, also known as hepatocellular carcinoma. These tumors are highly aggressive, with a five-year survival rate of less than ten percent. One reason for this is that current treatments are only effective to a limited extent.
In his Venture Fellowship project, Nicolas Melin, previously Postdoc at the Department of Visceral Surgery and Medicine at the Inselspital University Hospital Bern and the University of Bern, is developing a new therapy for hepatocellular carcinoma. This new precision therapy aims to significantly enhance the effectiveness of highly burdensome immunotherapies, and thereby improve the chances of survival of patients.
About the Venture Fellowships
The Venture Fellowship Program of the University of Bern was established with the aim of promoting the transfer of research and new technologies into economy and society.